Live Breaking News & Updates on Pat Inflamm Allergy Drug

Alcon Inc. Investors: Alcon Announces Broad Retail Availability of Pataday Once Daily Relief Extra Strength in the U.S.
1
The drop, formerly prescribed as Pazeo, joins Alcon s over-the-counter ocular allergy portfolio to meet a variety of patient needs
The expansion of the Pataday portfolio of products will strengthen Alcon s leadership position in the U.S. eye allergy OTC market
Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced that Pataday
Once Daily Relief Extra Strength (
olopatadine hydrochloride ophthalmic solution 0.7%) is now available in-store and online at U.S. retailers, following its 2020 approval by the Food and Drug Administration (FDA) for sale over-the-counter (OTC). As Alcon s third Rx-to-OTC switch in the past twelve months, Pataday Once Daily Relief Extra Strength joins the #1 selling OTC eye allergy relief brand and is poised to help the company maintain its leadership posit ....

United States , New York , Steven Smith , Alcon Pataday , Miraldi Utz , Tania Elliott , Christina Cheng , Sergio Duplan , Drug Administration , Exchange Commission , Nielsen Household Panel Data Feb , Alcon Inc , Pataday Once Daily Relief Extra Strength , Daily Relief Extra Strength , Once Daily Relief Extra Strength , Business Wire , Falcon North , Pataday Once Daily Relief , Pataday Twice Daily Relief , United States Securities , Vision Care , Opin Allergy Clin , Household Panel Data , Pat Inflamm Allergy Drug , Clin North , Allergy Clin ,